Loading...
•
Mar 31
CRISPR Therapeutics Q1 2025 Earnings Report
CRISPR Therapeutics reported its financial results for the first quarter ended March 31, 2025, and announced positive top-line data from its Phase 1 clinical trial of CTX310™ targeting ANGPTL3.
Key Takeaways
CRISPR Therapeutics reported a net loss of $136.0 million for Q1 2025, compared to a net loss of $116.6 million for Q1 2024. The company's total revenue for the quarter was $865 thousand, primarily from grant revenue. Research and development expenses decreased, while general and administrative and collaboration expenses increased.
Initial CTX310™ Phase 1 clinical data showed dose-dependent decreases in triglycerides (TG) and low-density lipoprotein (LDL), with peak reductions of up to 82% in TG and 81% in LDL, and a well-tolerated safety profile.
CASGEVY® continues to gain momentum with over 65 authorized treatment centers activated globally and more than 90 patients having had cells collected.
Clinical trial for CTX320™ targeting the LPA gene is ongoing, with top-line data update expected in Q2 2025.
The company maintains a strong balance sheet with approximately $1.86 billion in cash, cash equivalents, and marketable securities as of March 31, 2025.
CRISPR Therapeutics
CRISPR Therapeutics
CRISPR Therapeutics Revenue by Segment
Revenue by Segment
Grant Revenue
CapyFin.com Forward Guidance
CRISPR Therapeutics anticipates continued progress across its pipeline, including further clinical updates for CTX310, CTX320, CTX112, and CTX131, and expects significant growth in new patient initiations for CASGEVY in 2025.
Positive Outlook
- Presentation of CTX310 Phase 1 data at a medical meeting in the second half of 2025.
- Top-line data update for CTX320 on track for the second quarter of 2025.
- Broad updates for CTX112 in oncology and autoimmune diseases expected mid-2025, with CTX131 updates also expected in 2025.
- New patient initiations for CASGEVY expected to grow significantly throughout 2025.
- Commercial production of CASGEVY in Portsmouth, New Hampshire expected to begin in the second half of 2025.
Challenges Ahead
- The company's forward-looking statements are subject to risks and uncertainties, and actual results may differ materially.
- There is no guarantee that any investigational therapy will successfully complete clinical development or gain approval.
- Information regarding industry, business, and market data is based on estimates and forecasts, which are inherently subject to uncertainties.
- The press release does not convey conclusions about efficacy or safety of investigational therapies.
- No specific negative financial guidance or outlook was provided in the report.